Bollard Group’s Soleno Therapeutics, Inc. Series A Warrant SLNOW Stock Holding History

Bollard Group’s Portfolio SLNOW Stock Details SLNOW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-2,197	Closed	–	–	272
2017 Q4	$0	Hold	2,197	–	–	﹤0.01%	273
2017 Q3	$1K	Hold	2,197	–	–	﹤0.01%	266
2017 Q2	$2K	Buy	+2,197	New	+$2.01K	﹤0.01%	266

Other funds holding SLNOW

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Bollard Group's SLNOW Position: Q1 2018 in Review

Bollard Group sold out of Soleno Therapeutics, Inc. Series A Warrant (SLNOW) in Q1 2018, closing a stake of 2,197 shares.

Bollard Group first reported a position in SLNOW in Q2 2017 and held it in 3 quarters. The position peaked at $2K in Q2 2017. 3 funds tracked by Wall St. Rank hold SLNOW as of Q1 2018.

Bollard Group reported no remaining Soleno Therapeutics, Inc. Series A Warrant position as of Q1 2018 after selling out during the quarter.
Bollard Group sold 2,197 Soleno Therapeutics, Inc. Series A Warrant shares in Q1 2018.
Bollard Group first reported a position in Soleno Therapeutics, Inc. Series A Warrant in Q2 2017 and held it in 3 quarters.
Bollard Group's Soleno Therapeutics, Inc. Series A Warrant position peaked at $2K in Q2 2017.
3 funds tracked by Wall St. Rank held Soleno Therapeutics, Inc. Series A Warrant as of Q1 2018.

Based on Bollard Group's 13F filing for Q1 2018, filed 14 May 2018.